BioStock: Promising results in Chordate’s follow-up study

Chordate Medical has conducted an initial data analysis in the long-term study PM010 with its migraine treatment Ozilia. According to the company, the results are promising, both in terms of the primary and secondary endpoints. The company’s CEO, Anders Weilandt, shares more about the results in an interview with BioStock.

Read the full article at biostock.se:

https://www.biostock.se/en/2024/09/promising-results-in-chordates-follow-up-study/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se